Luisa Paschke
Luisa Paschke
Department of Endocrinology and Nephrology, Division of Endocrinology, University Clinic Leipzig, Leipzig, Germany
Department of Endocrinology and Nephrology, Division of Nephrology, University Clinic Leipzig, Leipzig, Germany
Search for other papers by Luisa Paschke in
Google Scholar
PubMed
Department of Endocrinology and Nephrology, Division of Nephrology, University Clinic Leipzig, Leipzig, Germany
Search for other papers by Luisa Paschke in
Google Scholar
PubMed
Thomas Lincke
Thomas Lincke
Department of Radiology, Division of Nuclear Medicine, University Clinic Leipzig, Leipzig, Germany
Search for other papers by Thomas Lincke in
Google Scholar
PubMed
Search for other papers by Thomas Lincke in
Google Scholar
PubMed
Katja Sibylle Mühlberg
Katja Sibylle Mühlberg
Department of Angiology, University Clinic Leipzig, Leipzig, Germany
Search for other papers by Katja Sibylle Mühlberg in
Google Scholar
PubMed
Search for other papers by Katja Sibylle Mühlberg in
Google Scholar
PubMed
Wolfram J. Jabs
Wolfram J. Jabs
Department of Nephrology, Vivantes Clinics, Berlin, Germany
Search for other papers by Wolfram J. Jabs in
Google Scholar
PubMed
Search for other papers by Wolfram J. Jabs in
Google Scholar
PubMed
Tom H. Lindner
Tom H. Lindner
Department of Endocrinology and Nephrology, Division of Nephrology, University Clinic Leipzig, Leipzig, Germany
Search for other papers by Tom H. Lindner in
Google Scholar
PubMed
Search for other papers by Tom H. Lindner in
Google Scholar
PubMed
Ralf Paschke
Ralf Paschke
Division of Endocrinology, University of Calgary, Calgary, Alberta, Canada
Search for other papers by Ralf Paschke in
Google Scholar
PubMed
Search for other papers by Ralf Paschke in
Google Scholar
PubMed
What Is Known about This Topic? Both phase III trials of cabozantinib and lenvatinib reported that renal adverse events occurred in rare cases. The phase III study of carbozantinib reported no adverse events (AEs) regarding renal toxicity
Lars Bastholt
Lars Bastholt
Department of Oncology R, Odense University Hospital, Odense, Denmark
Search for other papers by Lars Bastholt in
Google Scholar
PubMed
Search for other papers by Lars Bastholt in
Google Scholar
PubMed
Michael C. Kreissl
Michael C. Kreissl
Department of Nuclear Medicine, Augsburg Hospital, Augsburg
Department of Nuclear Medicine, University Hospital Würzburg, Würzburg
Search for other papers by Michael C. Kreissl in
Google Scholar
PubMed
Department of Nuclear Medicine, University Hospital Würzburg, Würzburg
Search for other papers by Michael C. Kreissl in
Google Scholar
PubMed
Dagmar Führer
Dagmar Führer
Department of Endocrinology and Metabolism, University Hospital Essen, Essen, Germany
Search for other papers by Dagmar Führer in
Google Scholar
PubMed
Search for other papers by Dagmar Führer in
Google Scholar
PubMed
Ana L. Maia
Ana L. Maia
Serviço de Endocrinologia, Hospital de Clínicas de Porto Alegre, Porto Alegre
Search for other papers by Ana L. Maia in
Google Scholar
PubMed
Search for other papers by Ana L. Maia in
Google Scholar
PubMed
Laura D. Locati
Laura D. Locati
Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan
Search for other papers by Laura D. Locati in
Google Scholar
PubMed
Search for other papers by Laura D. Locati in
Google Scholar
PubMed
Léa Maciel
Léa Maciel
Hospital das Clínicas de Ribeirăo Preto, Ribeirăo Preto, Brazil
Search for other papers by Léa Maciel in
Google Scholar
PubMed
Search for other papers by Léa Maciel in
Google Scholar
PubMed
Yi Wu
Yi Wu
Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
Search for other papers by Yi Wu in
Google Scholar
PubMed
Search for other papers by Yi Wu in
Google Scholar
PubMed
Kevin N. Heller
Kevin N. Heller
AstraZeneca, Gaithersburg, Md., USA
Search for other papers by Kevin N. Heller in
Google Scholar
PubMed
Search for other papers by Kevin N. Heller in
Google Scholar
PubMed
Alan Webster
Alan Webster
AstraZeneca, Macclesfield, UK
Search for other papers by Alan Webster in
Google Scholar
PubMed
Search for other papers by Alan Webster in
Google Scholar
PubMed
Rossella Elisei
Rossella Elisei
Endocrinology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
treatment decisions [ 14 ]. Across a number of clinical trials, the most common adverse events (AEs) in vandetanib-treated patients have been diarrhoea, rash, nausea, hypertension and headache [ 15 , 16 , 17 , 18 , 19 , 20 ], events consistent with the
Laura Valerio
Laura Valerio
Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Pisa, Italy
Search for other papers by Laura Valerio in
Google Scholar
PubMed
Search for other papers by Laura Valerio in
Google Scholar
PubMed
Carlotta Giani
Carlotta Giani
Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Pisa, Italy
Search for other papers by Carlotta Giani in
Google Scholar
PubMed
Search for other papers by Carlotta Giani in
Google Scholar
PubMed
Laura Agate
Laura Agate
Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Pisa, Italy
Search for other papers by Laura Agate in
Google Scholar
PubMed
Search for other papers by Laura Agate in
Google Scholar
PubMed
Eleonora Molinaro
Eleonora Molinaro
Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Pisa, Italy
Search for other papers by Eleonora Molinaro in
Google Scholar
PubMed
Search for other papers by Eleonora Molinaro in
Google Scholar
PubMed
David Viola
David Viola
Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Pisa, Italy
Search for other papers by David Viola in
Google Scholar
PubMed
Search for other papers by David Viola in
Google Scholar
PubMed
Valeria Bottici
Valeria Bottici
Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Pisa, Italy
Search for other papers by Valeria Bottici in
Google Scholar
PubMed
Search for other papers by Valeria Bottici in
Google Scholar
PubMed
Antonio Matrone
Antonio Matrone
Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Pisa, Italy
Search for other papers by Antonio Matrone in
Google Scholar
PubMed
Search for other papers by Antonio Matrone in
Google Scholar
PubMed
Luciana Puleo
Luciana Puleo
Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Pisa, Italy
Search for other papers by Luciana Puleo in
Google Scholar
PubMed
Search for other papers by Luciana Puleo in
Google Scholar
PubMed
Loredana Lorusso
Loredana Lorusso
Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Pisa, Italy
Search for other papers by Loredana Lorusso in
Google Scholar
PubMed
Search for other papers by Loredana Lorusso in
Google Scholar
PubMed
Virginia Cappagli
Virginia Cappagli
Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Pisa, Italy
Search for other papers by Virginia Cappagli in
Google Scholar
PubMed
Search for other papers by Virginia Cappagli in
Google Scholar
PubMed
Alessandro Ribechini
Alessandro Ribechini
Department of Thoracic Endoscopy, University Hospital of Pisa, Pisa, Italy
Search for other papers by Alessandro Ribechini in
Google Scholar
PubMed
Search for other papers by Alessandro Ribechini in
Google Scholar
PubMed
Rossella Elisei
Rossella Elisei
Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Pisa, Italy
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
analysis of the potential risk factors for these severe adverse events (AEs) was performed. Materials and Methods Patients This retrospective study included data from RAI-R DTC patients treated with lenvatinib from February 2011 to February 2020
Daniela Cavaco
Daniela Cavaco
Department of Endocrinology, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Search for other papers by Daniela Cavaco in
Google Scholar
PubMed
Search for other papers by Daniela Cavaco in
Google Scholar
PubMed
Sara Carvalhal
Sara Carvalhal
Department of General Surgery, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Search for other papers by Sara Carvalhal in
Google Scholar
PubMed
Search for other papers by Sara Carvalhal in
Google Scholar
PubMed
Valeriano Leite
Valeriano Leite
Department of Endocrinology, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
NOVA Medical School/ Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal
Search for other papers by Valeriano Leite in
Google Scholar
PubMed
NOVA Medical School
Search for other papers by Valeriano Leite in
Google Scholar
PubMed
institution and metastases were actively bleeding, imposing urgent care. ECT has the advantage of being performed in an ambulatory surgical unit with only half-day to 1 day of hospital stay and can be repeated several times. Since the most common ECT adverse
Pauline Campredon
Pauline Campredon
Department of Endocrinology and Metabolic Diseases, Larrey University Hospital, Toulouse, France
Search for other papers by Pauline Campredon in
Google Scholar
PubMed
Search for other papers by Pauline Campredon in
Google Scholar
PubMed
Philippe Imbert
Philippe Imbert
Ophthalmologist, Clinique du Parc, Toulouse, France
Multidisciplinary Thyroid Eye Consultation, Department of Endocrinology, Larrey University Hospital, Toulouse, France
Search for other papers by Philippe Imbert in
Google Scholar
PubMed
Multidisciplinary Thyroid Eye Consultation, Department of Endocrinology, Larrey University Hospital, Toulouse, France
Search for other papers by Philippe Imbert in
Google Scholar
PubMed
Céline Mouly
Céline Mouly
Department of Endocrinology and Metabolic Diseases, Larrey University Hospital, Toulouse, France
Search for other papers by Céline Mouly in
Google Scholar
PubMed
Search for other papers by Céline Mouly in
Google Scholar
PubMed
Solange Grunenwald
Solange Grunenwald
Department of Endocrinology and Metabolic Diseases, Larrey University Hospital, Toulouse, France
Search for other papers by Solange Grunenwald in
Google Scholar
PubMed
Search for other papers by Solange Grunenwald in
Google Scholar
PubMed
Julien Mazières
Julien Mazières
Department of Pneumology, Larrey University Hospital, Toulouse, France
Search for other papers by Julien Mazières in
Google Scholar
PubMed
Search for other papers by Julien Mazières in
Google Scholar
PubMed
Philippe Caron
Philippe Caron
Department of Endocrinology and Metabolic Diseases, Larrey University Hospital, Toulouse, France
Search for other papers by Philippe Caron in
Google Scholar
PubMed
Search for other papers by Philippe Caron in
Google Scholar
PubMed
What Is Known about This Topic? Anti-PD-1 monoclonal antibody therapy is associated with immune-related adverse events, and the most frequent is inflammatory thyroiditis. During immunotherapy, immune-related ocular toxicities are
Carla Gambale
Carla Gambale
Department of Clinical and Experimental Medicine, Unit of Endocrinology, Pisa University Hospital, Pisa, Italy
Search for other papers by Carla Gambale in
Google Scholar
PubMed
Search for other papers by Carla Gambale in
Google Scholar
PubMed
Alessandro Prete
Alessandro Prete
Department of Clinical and Experimental Medicine, Unit of Endocrinology, Pisa University Hospital, Pisa, Italy
Search for other papers by Alessandro Prete in
Google Scholar
PubMed
Search for other papers by Alessandro Prete in
Google Scholar
PubMed
Chiara Romei
Chiara Romei
Department of Diagnostic Imaging, Unit of Radiology, Pisa University Hospital, Pisa, Italy
Search for other papers by Chiara Romei in
Google Scholar
PubMed
Search for other papers by Chiara Romei in
Google Scholar
PubMed
Alessandro Celi
Alessandro Celi
Department of Surgery, Medicine, Molecular Biology and Critical Care, Respiratory Pathophysiology Unit, Pisa University Hospital, Pisa, Italy
Search for other papers by Alessandro Celi in
Google Scholar
PubMed
Search for other papers by Alessandro Celi in
Google Scholar
PubMed
Rossella Elisei
Rossella Elisei
Department of Clinical and Experimental Medicine, Unit of Endocrinology, Pisa University Hospital, Pisa, Italy
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
Antonio Matrone
Antonio Matrone
Department of Clinical and Experimental Medicine, Unit of Endocrinology, Pisa University Hospital, Pisa, Italy
Search for other papers by Antonio Matrone in
Google Scholar
PubMed
Search for other papers by Antonio Matrone in
Google Scholar
PubMed
inhibitors, atypical adverse events have been described. Novel insights We present the first reported case of obliterative bronchiolitis occurring during treatment with selpercatinib in an advanced RET-mutant medullary thyroid cancer
Alice Nervo
Alice Nervo
Oncological Endocrinology Unit, Department of Medical Sciences, University of Turin, Città della Salute e della Scienza Hospital, Turin, Italy
Search for other papers by Alice Nervo in
Google Scholar
PubMed
Search for other papers by Alice Nervo in
Google Scholar
PubMed
Alberto Ragni
Alberto Ragni
Oncological Endocrinology Unit, Department of Medical Sciences, University of Turin, Città della Salute e della Scienza Hospital, Turin, Italy
Search for other papers by Alberto Ragni in
Google Scholar
PubMed
Search for other papers by Alberto Ragni in
Google Scholar
PubMed
Alessandro Piovesan
Alessandro Piovesan
Oncological Endocrinology Unit, Department of Medical Sciences, University of Turin, Città della Salute e della Scienza Hospital, Turin, Italy
Search for other papers by Alessandro Piovesan in
Google Scholar
PubMed
Search for other papers by Alessandro Piovesan in
Google Scholar
PubMed
Valentina Marica
Valentina Marica
Oncological Endocrinology Unit, Department of Medical Sciences, University of Turin, Città della Salute e della Scienza Hospital, Turin, Italy
Search for other papers by Valentina Marica in
Google Scholar
PubMed
Search for other papers by Valentina Marica in
Google Scholar
PubMed
Enrica Migliore
Enrica Migliore
Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin, Città della Salute e della Scienza Hospital, Turin, Italy
Search for other papers by Enrica Migliore in
Google Scholar
PubMed
Search for other papers by Enrica Migliore in
Google Scholar
PubMed
Marco Gallo
Marco Gallo
Oncological Endocrinology Unit, Department of Medical Sciences, University of Turin, Città della Salute e della Scienza Hospital, Turin, Italy
Search for other papers by Marco Gallo in
Google Scholar
PubMed
Search for other papers by Marco Gallo in
Google Scholar
PubMed
Emanuela Arvat
Emanuela Arvat
Oncological Endocrinology Unit, Department of Medical Sciences, University of Turin, Città della Salute e della Scienza Hospital, Turin, Italy
Search for other papers by Emanuela Arvat in
Google Scholar
PubMed
Search for other papers by Emanuela Arvat in
Google Scholar
PubMed
-life setting [ 1 - 4 ]. Nevertheless, frequent onset of adverse events (AEs) may decrease patients’ compliance and, in some cases, lead to discontinuation of therapy [ 5 ]. In recent years, growing interest has been dedicated to the study of the quality of
Carla Colombo
Carla Colombo
Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano, IRCCS, Milan, Italy
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Carla Colombo in
Google Scholar
PubMed
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Carla Colombo in
Google Scholar
PubMed
Daniele Ceruti
Daniele Ceruti
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Daniele Ceruti in
Google Scholar
PubMed
Search for other papers by Daniele Ceruti in
Google Scholar
PubMed
Simone De Leo
Simone De Leo
Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano, IRCCS, Milan, Italy
Search for other papers by Simone De Leo in
Google Scholar
PubMed
Search for other papers by Simone De Leo in
Google Scholar
PubMed
Grzegorz Bilo
Grzegorz Bilo
Department of Cardiology, San Luca Hospital, Istituto Auxologico Italiano, IRCCS, Milan, Italy
Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy
Search for other papers by Grzegorz Bilo in
Google Scholar
PubMed
Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy
Search for other papers by Grzegorz Bilo in
Google Scholar
PubMed
Matteo Trevisan
Matteo Trevisan
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Matteo Trevisan in
Google Scholar
PubMed
Search for other papers by Matteo Trevisan in
Google Scholar
PubMed
Noemi Giancola
Noemi Giancola
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Noemi Giancola in
Google Scholar
PubMed
Search for other papers by Noemi Giancola in
Google Scholar
PubMed
Claudia Moneta
Claudia Moneta
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Claudia Moneta in
Google Scholar
PubMed
Search for other papers by Claudia Moneta in
Google Scholar
PubMed
Gianfranco Parati
Gianfranco Parati
Department of Cardiology, San Luca Hospital, Istituto Auxologico Italiano, IRCCS, Milan, Italy
Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy
Search for other papers by Gianfranco Parati in
Google Scholar
PubMed
Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy
Search for other papers by Gianfranco Parati in
Google Scholar
PubMed
Luca Persani
Luca Persani
Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano, IRCCS, Milan, Italy
Department of Biotechnology and Translational Medicine, University of Milan, Milan, Italy
Search for other papers by Luca Persani in
Google Scholar
PubMed
Department of Biotechnology and Translational Medicine, University of Milan, Milan, Italy
Search for other papers by Luca Persani in
Google Scholar
PubMed
Laura Fugazzola
Laura Fugazzola
Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano, IRCCS, Milan, Italy
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Laura Fugazzola in
Google Scholar
PubMed
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Laura Fugazzola in
Google Scholar
PubMed
demonstrated significantly prolonged progression-free survival (PFS) ( 4 , 5 , 6 , 7 , 8 ). The occurrence of several adverse events (AEs) has been reported, particularly during treatment with anti-angiogenic drugs: hypertension (HTN), diarrhoea
Mikael Lantz
Mikael Lantz
Department of Endocrinology and Ophthalmology, Skåne University Hospital Malmö, Malmö
Department of Clinical Sciences, Lund University, Lund
Search for other papers by Mikael Lantz in
Google Scholar
PubMed
Department of Clinical Sciences, Lund University, Lund
Search for other papers by Mikael Lantz in
Google Scholar
PubMed
Jan Calissendorff
Jan Calissendorff
Karolinska Institutet, Department of Clinical Science and Education, Södersjukhuset
Search for other papers by Jan Calissendorff in
Google Scholar
PubMed
Search for other papers by Jan Calissendorff in
Google Scholar
PubMed
Frank Träisk
Frank Träisk
Department of Clinical Neurosciences, St. Erik Eye Hospital, Karolinska Institutet, Stockholm, Sweden
Search for other papers by Frank Träisk in
Google Scholar
PubMed
Search for other papers by Frank Träisk in
Google Scholar
PubMed
Leif Tallstedt
Leif Tallstedt
Department of Clinical Neurosciences, St. Erik Eye Hospital, Karolinska Institutet, Stockholm, Sweden
Search for other papers by Leif Tallstedt in
Google Scholar
PubMed
Search for other papers by Leif Tallstedt in
Google Scholar
PubMed
Tereza Planck
Tereza Planck
Department of Endocrinology and Ophthalmology, Skåne University Hospital Malmö, Malmö
Department of Clinical Sciences, Lund University, Lund
Search for other papers by Tereza Planck in
Google Scholar
PubMed
Department of Clinical Sciences, Lund University, Lund
Search for other papers by Tereza Planck in
Google Scholar
PubMed
Ove Törring
Ove Törring
Karolinska Institutet, Department of Clinical Science and Education, Södersjukhuset
Search for other papers by Ove Törring in
Google Scholar
PubMed
Search for other papers by Ove Törring in
Google Scholar
PubMed
Bengt Hallengren
Bengt Hallengren
Department of Endocrinology and Ophthalmology, Skåne University Hospital Malmö, Malmö
Department of Clinical Sciences, Lund University, Lund
Search for other papers by Bengt Hallengren in
Google Scholar
PubMed
Department of Clinical Sciences, Lund University, Lund
Search for other papers by Bengt Hallengren in
Google Scholar
PubMed
Peter Åsman
Peter Åsman
Department of Endocrinology and Ophthalmology, Skåne University Hospital Malmö, Malmö
Department of Clinical Sciences, Lund University, Lund
Search for other papers by Peter Åsman in
Google Scholar
PubMed
Department of Clinical Sciences, Lund University, Lund
Search for other papers by Peter Åsman in
Google Scholar
PubMed
related to treatment with methimazole (table 3 ). Other methimazole-related adverse events reported were skin reactions, loss of taste and joint pain/swollenness. None of these events differed significantly between the groups. Gastrointestinal symptoms
Jaume Capdevila
Jaume Capdevila
Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), IOB Quiron-Teknon, Barcelona, Spain
Search for other papers by Jaume Capdevila in
Google Scholar
PubMed
Search for other papers by Jaume Capdevila in
Google Scholar
PubMed
Desiree’ Deandreis
Desiree’ Deandreis
Department of Medical Sciences, Nuclear Medicine Unit, University of Turin, AOU Città della Salute e della Scienza, Turin, Italy
Search for other papers by Desiree’ Deandreis in
Google Scholar
PubMed
Search for other papers by Desiree’ Deandreis in
Google Scholar
PubMed
Cosimo Durante
Cosimo Durante
Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy
Search for other papers by Cosimo Durante in
Google Scholar
PubMed
Search for other papers by Cosimo Durante in
Google Scholar
PubMed
Sophie Leboulleux
Sophie Leboulleux
Service of Endocrinology, Diabetology, University Hospital Geneve, Geneve, Switzerland
Search for other papers by Sophie Leboulleux in
Google Scholar
PubMed
Search for other papers by Sophie Leboulleux in
Google Scholar
PubMed
Markus Luster
Markus Luster
Department of Nuclear Medicine, University Hospital Marburg, Marburg, Germany
Search for other papers by Markus Luster in
Google Scholar
PubMed
Search for other papers by Markus Luster in
Google Scholar
PubMed
Romana Netea-Maier
Romana Netea-Maier
Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, The Netherlands
Search for other papers by Romana Netea-Maier in
Google Scholar
PubMed
Search for other papers by Romana Netea-Maier in
Google Scholar
PubMed
Kate Newbold
Kate Newbold
Royal Marsden Hospital, London, United Kingdom
Search for other papers by Kate Newbold in
Google Scholar
PubMed
Search for other papers by Kate Newbold in
Google Scholar
PubMed
Susanne Singer
Susanne Singer
Institute of Medical Biostatistics Epidemiology and Informatics (IMBEI), University Medical Center of Johannes Gutenberg University, Mainz, Germany
Search for other papers by Susanne Singer in
Google Scholar
PubMed
Search for other papers by Susanne Singer in
Google Scholar
PubMed
Gerasimos P Sykiotis
Gerasimos P Sykiotis
Service of Endocrinology, Diabetology and Metabolism, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
Search for other papers by Gerasimos P Sykiotis in
Google Scholar
PubMed
Search for other papers by Gerasimos P Sykiotis in
Google Scholar
PubMed
Beate Bartes
Beate Bartes
Association “Vivre sans Thyroïde”, Léguevin, France
Search for other papers by Beate Bartes in
Google Scholar
PubMed
Search for other papers by Beate Bartes in
Google Scholar
PubMed
Kate Farnell
Kate Farnell
Butterfly Thyroid Cancer Trust, Rowlands Gill, Tyne & Wear, UK
Search for other papers by Kate Farnell in
Google Scholar
PubMed
Search for other papers by Kate Farnell in
Google Scholar
PubMed
Laura Deborah Locati
Laura Deborah Locati
Medical Oncology Unit, IRCCS ICS Maugeri, Pavia, Italy
Department of Internal Medicine and Therapeutics, University of Pavia, Italy
Search for other papers by Laura Deborah Locati in
Google Scholar
PubMed
Department of Internal Medicine and Therapeutics, University of Pavia, Italy
Search for other papers by Laura Deborah Locati in
Google Scholar
PubMed
no BRAF/MEK inhibitors have been approved up to now in Europe. Since MKIs are associated with substantial adverse events (AEs) such as hypertension, diarrhea, fatigue, and weight loss, and since they are expected to be administered on a long-term term
